# Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers

> **NCT03836859** · PHASE1 · COMPLETED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 30 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** rhNGF 20μg/mL
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03836859
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-30
- **Primary completion:** 2018-06-01
- **Final completion:** 2018-06-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03836859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03836859, "Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03836859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*